Genzyme's Mozobil approved in EU
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation for Genzyme's Mozobil (plerixafor) for patients with lymphoma and multiple myeloma who require autologous stem cell transplants. It is indicated in combination with granulocyte-colony stimulating factor to enhance mobilisation of stem cells.